• Why Most Immune-Driven Diseases Are Managed, Not Cured.
• Across oncology, autoimmune diseases, and transplant medicine, modern therapies have improved short-term outcomes. Yet relapse remains common, treatment is often lifelong, and costs continue to rise.
• Most current approaches rely on immune suppression or direct targeting of diseased tissues. These strategies can control symptoms, but they do not correct the immune dysfunction that allows disease to persist.
• Disease control has improved. Durable disease resolution has not.
The Disease Is Embedded in the Immune System
Many serious diseases are now understood as system-level immune disorders. Central to immune regulation is the T-cell compartment, which governs immune activation, tolerance, and memory.
When this regulatory system becomes pathologically altered, downstream treatments can only provide temporary benefit. Disease persists because abnormal immune programming remains within the immune system itself.
Resolving these diseases requires addressing immune regulation, not only downstream effects.
From Immune Suppression to Immune Reset
VG712 is a clinically validated approach designed to reset the immune system.
By clearing pathogenic T-cell states and allowing immune reconstitution, VG712 introduces a fundamentally different strategy with relevance across multiple immune-driven diseases.
VG712 is not incremental. It represents a new therapeutic paradigm.